chloroquine has been researched along with Acute Myelogenous Leukemia in 15 studies
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.
chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Current therapy for acute myeloid leukemia (AML) is largely hindered by the development of drug resistance of commonly used chemotherapy drugs, including cytarabine, daunorubicin, and idarubicin." | 1.91 | Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway. ( Feng, B; Fu, JF; Kan, WJ; Li, J; Li, JN; Liu, MM; Luo, GH; Song, N; Tu, YT; Wang, HL; Wei, G; Wu, WB; Xu, GY; Xu, R; Zhou, YB, 2023) |
| "However, the impact of autophagy on acute myeloid leukemia (AML) maintenance and the validity of autophagy as a viable target in AML therapy remain unclear." | 1.46 | Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine. ( Chen, S; Chen, X; Clark, J; Davis, A; Fan, C; Guan, JL; Kumar, A; Mulloy, JC; Wunderlich, M; Zheng, Y, 2017) |
| "Three patients with aplastic anaemia following chloroquine therapy are described." | 1.26 | Aplasia and leukaemia following chloroquine therapy. ( Chetiyawardana, AD; Nagaratnam, N; Rajiyah, S, 1978) |
| "In a patient with acute myelogenous leukemia infected with Plasmodium vivax, neither his underlying disease nor intensive cytotoxic chemotherapy appeared to ameliorate or worsen the clinical course of his infection." | 1.26 | Malaria complicating neoplastic disease. ( Armstrong, D; Tapper, ML, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (40.00) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, X | 1 |
| Jiang, Y | 1 |
| Peterson, YK | 1 |
| Xu, T | 1 |
| Himes, RA | 1 |
| Luo, X | 1 |
| Yin, G | 1 |
| Inks, ES | 1 |
| Dolloff, N | 1 |
| Halene, S | 1 |
| Chan, SSL | 1 |
| Chou, CJ | 1 |
| Wang, HL | 1 |
| Li, JN | 1 |
| Kan, WJ | 1 |
| Xu, GY | 1 |
| Luo, GH | 1 |
| Song, N | 1 |
| Wu, WB | 1 |
| Feng, B | 1 |
| Fu, JF | 1 |
| Tu, YT | 1 |
| Liu, MM | 1 |
| Xu, R | 1 |
| Zhou, YB | 1 |
| Wei, G | 1 |
| Li, J | 1 |
| Visser, N | 1 |
| Lourens, HJ | 1 |
| Huls, G | 1 |
| Bremer, E | 1 |
| Wiersma, VR | 1 |
| Torgersen, ML | 1 |
| Engedal, N | 1 |
| Bøe, SO | 1 |
| Hokland, P | 1 |
| Simonsen, A | 1 |
| Xie, N | 1 |
| Zhong, L | 1 |
| Liu, L | 1 |
| Fang, Y | 1 |
| Qi, X | 1 |
| Cao, J | 1 |
| Yang, B | 1 |
| He, Q | 1 |
| Ying, M | 1 |
| Davood, ZA | 1 |
| Shamsi, S | 1 |
| Ghaedi, H | 1 |
| Sahand, RI | 1 |
| Mojtaba, G | 1 |
| Mahdi, T | 1 |
| Reza, M | 1 |
| Ebrahimi, MJ | 1 |
| Miri-Moosavi, RS | 1 |
| Boosaliki, S | 1 |
| Davood, OM | 1 |
| Chen, X | 1 |
| Clark, J | 1 |
| Wunderlich, M | 1 |
| Fan, C | 1 |
| Davis, A | 1 |
| Chen, S | 1 |
| Guan, JL | 1 |
| Mulloy, JC | 1 |
| Kumar, A | 2 |
| Zheng, Y | 1 |
| Yan, ZW | 1 |
| Hou, JK | 1 |
| He, W | 1 |
| Fan, L | 1 |
| Huang, Y | 1 |
| Stein, BS | 1 |
| Bensch, KG | 1 |
| Sussman, HH | 1 |
| Ferrante, A | 1 |
| Goh, DH | 1 |
| Kapoor, AK | 1 |
| Lal, B | 1 |
| Dutta, GP | 1 |
| Swaroop, A | 1 |
| Nagaratnam, N | 1 |
| Chetiyawardana, AD | 1 |
| Rajiyah, S | 1 |
| Tapper, ML | 1 |
| Armstrong, D | 1 |
| Akin, DT | 1 |
| Kinkade, JM | 1 |
| Via, DP | 1 |
| Plant, AL | 1 |
| Craig, IF | 1 |
| Gotto, AM | 1 |
| Smith, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia[NCT05042531] | 30 participants (Anticipated) | Interventional | 2021-11-13 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
15 other studies available for chloroquine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Design; fms-Like Tyrosine Kinase 3; Histone D | 2020 |
Chloroquine enhances the efficacy of chemotherapy drugs against acute myeloid leukemia by inactivating the autophagy pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Chloroquine; Cytarabine; Daunorubicin; Hu | 2023 |
Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Line, Tumor; Chloroquine; Cytarabine; Drug Resistan | 2021 |
Targeting autophagy potentiates the apoptotic effect of histone deacetylase inhibitors in t(8;21) AML cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Chloroquine; | 2013 |
Autophagy contributes to dasatinib-induced myeloid differentiation of human acute myeloid leukemia cells.
Topics: Androstadienes; Autophagy; Cell Differentiation; Cell Line, Tumor; Chloroquine; Chromones; Dasatinib | 2014 |
Valproic acid may exerts its cytotoxic effect through rassf1a expression induction in acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Chloroquine; Drug Synergism; Female; Histone Deacetylase Inhibitors; Hu | 2016 |
Autophagy is dispensable for Kmt2a/Mll-Mllt3/Af9 AML maintenance and anti-leukemic effect of chloroquine.
Topics: Animals; Autophagy; Cell Line, Tumor; Chloroquine; Drug Resistance, Neoplasm; Histone-Lysine N-Methy | 2017 |
Chloroquine enhances cobalt chloride-induced leukemic cell differentiation via the suppression of autophagy at the late phase.
Topics: Autophagy; Cell Differentiation; Cell Line, Tumor; Chloroquine; Cobalt; Humans; Hypoxia-Inducible Fa | 2013 |
Complete inhibition of transferrin recycling by monensin in K562 cells.
Topics: Cell Line; Chloroquine; Fluorescent Antibody Technique; Furans; Humans; Kinetics; Leukemia, Myeloid, | 1984 |
The effect of anti-malarial drugs on human natural killer cells in vitro.
Topics: Antimalarials; Cell Line; Chloroquine; Cytotoxicity, Immunologic; Humans; Killer Cells, Natural; Leu | 1984 |
Plasmodium falciparum: drug-resistant malaria complicating leukemias and lymphomas in children.
Topics: Adolescent; Animals; Antimalarials; Child; Child, Preschool; Chloroquine; Drug Resistance; Drug Ther | 1999 |
Aplasia and leukaemia following chloroquine therapy.
Topics: Adult; Anemia, Aplastic; Bone Marrow; Chloroquine; Female; Humans; Leukemia, Myeloid, Acute; Malaria | 1978 |
Malaria complicating neoplastic disease.
Topics: Adult; Antibodies; Antibody Formation; Chloroquine; Colonic Neoplasms; Female; Hemostasis, Surgical; | 1976 |
Processing of a newly identified intermediate of human myeloperoxidase in isolated granules occurs at neutral pH.
Topics: Ammonium Chloride; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Chloroquine; Cytoplasmic Gran | 1986 |
Metabolism of normal and modified low-density lipoproteins by macrophage cell lines of murine and human origin.
Topics: Animals; Cell Line; Chloroquine; Cholesterol Esters; Humans; Leukemia P388; Leukemia, Myeloid, Acute | 1985 |